ecancermedicalscience

Short Communication

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy

28 Feb 2017
Herman Andrés Perroud, O Graciela Scharovsky, Viviana Rosa Rozados, Carlos María Alasino

Ovarian cancer (OC) is the leading cause of death from gynaecological cancer. It is extremely hard to diagnose in the early stages and around 70% of patients present with advanced disease. Metronomic chemotherapy (MCT) is described as the chronic administration of, generally low, equally spaced, doses of chemotherapeutic drugs with therapeutic efficacy and low toxicity. This is an effective and low-cost way to treat several types of tumours, including ovarian cancer. Here, we present six cases of advanced ovarian cancer treated with MCT with low doses of cyclophosphamide, which showed clinical response and stable disease.

Related Articles

Adu Bukola Gift, Michael Joseph Otorkpa, Oluwatobi O. Olayode, Ebubechukwu David Joseph, Ademola Abdulhakeem, Efuetlateh John Paul Nchonganyi, Feziechi Chikelundu Anele, Akolade Akeem Habib, Fodop Samuel Ghislain Junior, Oluwanifemi O. Akintoye, Omoregbee Benjamin
Rima Saad Rassam, Ryan R Lion, Siham Cherkaoui, Laila Hessissen, Ximena Garcia-Quintero, Lama Sayegh Najjar, Dolly Noun, Janane Hanna, Rana Yamout, Shahzadi Resham, Khaled Al Habaiba, Anwar Al-Nassan, Joe El-Khoury, Spandana Rayala, Qutaibah Alotaibi, Nahla Gafer, Giuseppe Troisi, Julia Downing, Suheir Rasul, Sima Jeha, Monnie Abraham, Michael J McNeil
Mevhibe B Hocaoglu, Grant Lewison, Hamish Sharp, Tania Pastrana, Eve Namisango, James Cleary, Barbara Hasties, Eric Kabisa, Helena Musau, Kathryn Spangenberg, Paola Ruiz, Zipporah Ali, Mertixell Mallafre-Larrosa, Alfredo Polo, Julie Torode, Ajay Aggarwal, Richard Sullivan